Louis Krane, MD
Urology · New Orleans, LANPI 1104013234
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $49,031 of the $61,823 with a category attached, or 79.3%. Angiodynamics, Inc. accounts for 95.0% of it on its own, with 32 other manufacturers making up the rest. 2025 is the largest year on record at $32,660, more than ten times the $1,238 reported in 2019. Among urology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 148 payments — averaging $417.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$59K
- Agiliti Surgical, Inc.$706
- Pfizer$304
- Urogen Pharma, Inc.$299
- Astellas Pharma US Inc$176
- Johnson & Johnson$173
- plus $1K from 27 others
Across 29 payments — averaging $3287.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Olympus Corporation Of The Americas$54K
- Dendreon Pharmaceuticals LLC$26K
- Janssen Research & Development, LLC$14K
- Gyrus ACMI, Inc.$2K
What the payments were for
- Consulting fees$49,03179%
- Travel & lodging$7,20112%
- Food & beverage$5,5919%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 63 | $58,705 |
| Agiliti Surgical, Inc. | 7 | $706 |
| Pfizer | 9 | $304 |
| Urogen Pharma, Inc. | 8 | $299 |
| Astellas Pharma US Inc | 8 | $176 |
| Johnson & Johnson(2 entities) | 7 | $173 |
| Boston Scientific | 5 | $166 |
| Dendreon Pharmaceuticals LLC | 4 | $156 |
| Teleflex LLC | 1 | $143 |
| Procept Biorobotics Corporation | 1 | $128 |
| Sumitomo Pharma America, Inc. | 5 | $116 |
| EMD Serono, Inc. | 1 | $111 |
| Merck | 3 | $61 |
| Progenics Pharmaceuticals, Inc. | 2 | $59 |
| Profound Medical Corp. | 1 | $57 |
| Coloplast | 2 | $48 |
| Varian Medical Systems, Inc. | 1 | $40 |
| Intuitive Surgical | 2 | $38 |
| Sanofi | 2 | $38 |
| Myriad Genetic Laboratories, Inc. | 2 | $30 |
| Antares Pharma, Inc. | 2 | $28 |
| Ambu Inc. | 1 | $25 |
| AbbVie | 1 | $23 |
| Bayer | 1 | $22 |
| Urovant Sciences Inc | 1 | $22 |
| Cook Medical LLC | 1 | $21 |
| Endo USA, Inc. | 1 | $21 |
| Hollister Incorporated | 1 | $20 |
| Telix Pharmaceuticals | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Civco Medical Instruments | 1 | $18 |
| Clarus Therapeutics Inc. | 1 | $16 |
| Acerus Pharmaceuticals Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nanoknife$57,741
- JELMYTO$138
- XTANDI$135
- AquaBeam Robotic System$128
How this compares
$61,823 in reported general payments places this provider in the 95th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 17 | $16,383 |
| Tamsulosin Hcl | 98 | $1,005 |
| Tolterodine Tartrate ErTolterodine Tartrate | 12 | $907 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 38 | $688 |
| Testosterone Cypionate | 16 | $606 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 16 | $314 |
| Finasteride | 25 | $230 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 16 | $29 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $176 | $16,38317 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 199 urology providers in Louisiana.
Other urology in New Orleans
- Richard VanlangendonckNew Orleans$289K
- Wayne HellstromNew Orleans$183K
- Colin GoudelockeNew Orleans$124K
- Raju ThomasNew Orleans$67K
- Jorge CasoNew Orleans$54K
- Lawrence JenkinsNew Orleans$33K
- Alexis ChesrowNew Orleans$17K
- Joanna TogamiNew Orleans$10K
- Neil BaumNew Orleans$9K
- Kyle RoseNew Orleans$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.